MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Monoclonal and Polyclonal Antibodies Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,236 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,236 works in the cohort · of 4,299,418page 26 of 45

Labels cover 5 of 2,236 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,236 of 2,236 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study.
Angeles Alvarez Secord, Lisa Barroilhet, Myong Cheol Lim, Sunil Gupta, Sonia Oosman, Jada Srinivas Rao +11 more
2022· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
Bovine Reaginic Antibody
K.H. Nielsen, B.N. Wilkie
2009· article· en· International Archives of Allergy and Applied Immunology· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affgemma · no categorygpt · no categorymodels agree
Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials
Jonathan C. Strefford, Małgorzata Nowicka, Chantal E. Hargreaves, Chisako Iriyama, Kate V. Latham, Rosalind Ganderton +14 more
2018· article· en· Blood· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
Monoclonal Antibodies in Cancer Immunotherapy
Xuqing Liu, Yunzhe Xu, Muyang Zhang
2023· article· en· Highlights in Science Engineering and Technology· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
Bovine Reaginic Antibody
K. Nielsen, Wendy Holmes, B.N. Wilkie, I.R. Tizard
2009· article· en· International Archives of Allergy and Applied Immunology· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affunlabeled
Principles of Immunoassays
Claudia Sheedy, Kerrm Y. F. Yau
2010· other· en· Medicine
machine prediction:candidate · noneconsensus · none
3
citations

How this was built: Screen · Findings · About